View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
August 31, 2020updated 12 Jul 2022 11:39am

Ashvattha unit Orpheris enrols first patients in Phase II PRANA trial

Biotechnology company Ashvattha Therapeutics’ wholly-owned subsidiary Orpheris has enrolled the first patients in its multicentre Phase II PRANA clinical trial of hydroxyl dendrimer therapeutic (HPT) OP-101.

Biotechnology company Ashvattha Therapeutics’ wholly-owned subsidiary Orpheris has enrolled the first patients in its multicentre Phase II PRANA clinical trial of hydroxyl dendrimer therapeutic (HPT) OP-101.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Under this clinical study, hospitalised adults with severe Covid-19 will be treated.

PRANA is a double-blind, placebo-controlled Phase II clinical trial that evaluates the efficacy of OP-101 in patients with severe Covid-19 as defined by the ordinal score of the World Health Organization (WHO).

The trial will see the enrolment of about 24 patients who will be randomised to receive a single intravenous (IV) infusion of OP-101 (2mg/kg, 4mg/kg or 8mg/kg) or placebo, in addition to the standard of care therapy.

According to Ashvattha, the primary endpoint of the study is safety and tolerability, while the secondary endpoints include efficiency as measured by resolution of fever, improvement in oxygenation, as well as discharge from hospital,

Also included under the secondary endpoints are the number of days free from a ventilator and the number of days in the ICU.

Emory University School of Medicine PRANA study investigator Ishan Mehta said: “Patients with severe Covid-19 can deteriorate rapidly because their immune response to the SARS-CoV-2 virus is exaggerated. This results in hyperinflammation, tissue damage and a cytokine storm, which can lead to lung injury.

“OP-101 is a promising treatment for this patient group due to its ability to selectively target reactive macrophages in the lungs. Patients hospitalised with severe Covid-19 are in desperate need of novel treatments that can accelerate their recovery, reduce length of critical illness and potentially avoid prolonged hospitalisation.”

The study will also analyse the effect of OP-101 in reducing blood levels of pro-inflammatory biomarkers such as C – reactive protein, ferritin as well as interleukin-6 after a single dosage of OP-101.

Initial data from the Phase II proof-of-concept (POC) study is expected to be released in the fourth quarter this year.

Ashvattha Therapeutics CEO and Orpheris executive chairman Jeffrey Cleland said: “With all five clinical trial sites up and running, we are eager to complete enrollment of very sick Covid-19 patients on oxygen and ventilators in our Phase II study.

“As the pandemic continues to spread in the United States and globally, novel approaches that can reduce the devastating effect of hyperinflammation in critically ill hospitalised patients are urgently needed.”

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena